Exploiting the peptidoglycan-binding motif, LysM, for medical and industrial applications

The lysin motif (LysM) was first identified by Garvey et al. in 1986 and, in subsequent studies, has been shown to bind noncovalently to peptidoglycan and chitin by interacting with N-acetylglucosamine moieties. The LysM sequence is present singly or repeatedly in a large number of proteins of proka...

Descripción completa

Detalles Bibliográficos
Autores principales: Visweswaran, Ganesh Ram R., Leenhouts, Kees, van Roosmalen, Maarten, Kok, Jan, Buist, Girbe
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4004799/
https://www.ncbi.nlm.nih.gov/pubmed/24652063
http://dx.doi.org/10.1007/s00253-014-5633-7
_version_ 1782314013587144704
author Visweswaran, Ganesh Ram R.
Leenhouts, Kees
van Roosmalen, Maarten
Kok, Jan
Buist, Girbe
author_facet Visweswaran, Ganesh Ram R.
Leenhouts, Kees
van Roosmalen, Maarten
Kok, Jan
Buist, Girbe
author_sort Visweswaran, Ganesh Ram R.
collection PubMed
description The lysin motif (LysM) was first identified by Garvey et al. in 1986 and, in subsequent studies, has been shown to bind noncovalently to peptidoglycan and chitin by interacting with N-acetylglucosamine moieties. The LysM sequence is present singly or repeatedly in a large number of proteins of prokaryotes and eukaryotes. Since the mid-1990s, domains containing one or more of these LysM sequences originating from different LysM-containing proteins have been examined for purely scientific reasons as well as for their possible use in various medical and industrial applications. These studies range from detecting localized binding of LysM-containing proteins onto bacteria to actual bacterial cell surface analysis. On a more applied level, the possibilities of employing the LysM domains for cell immobilization, for the display of peptides, proteins, or enzymes on (bacterial) surfaces as well as their utility in the development of novel vaccines have been scrutinized. To serve these purposes, the chimeric proteins containing one or more of the LysM sequences have been produced and isolated from various prokaryotic and eukaryotic expression hosts. This review gives a succinct overview of the characteristics of the LysM domain and of current developments in its application potential.
format Online
Article
Text
id pubmed-4004799
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher Springer Berlin Heidelberg
record_format MEDLINE/PubMed
spelling pubmed-40047992014-05-07 Exploiting the peptidoglycan-binding motif, LysM, for medical and industrial applications Visweswaran, Ganesh Ram R. Leenhouts, Kees van Roosmalen, Maarten Kok, Jan Buist, Girbe Appl Microbiol Biotechnol Mini-Review The lysin motif (LysM) was first identified by Garvey et al. in 1986 and, in subsequent studies, has been shown to bind noncovalently to peptidoglycan and chitin by interacting with N-acetylglucosamine moieties. The LysM sequence is present singly or repeatedly in a large number of proteins of prokaryotes and eukaryotes. Since the mid-1990s, domains containing one or more of these LysM sequences originating from different LysM-containing proteins have been examined for purely scientific reasons as well as for their possible use in various medical and industrial applications. These studies range from detecting localized binding of LysM-containing proteins onto bacteria to actual bacterial cell surface analysis. On a more applied level, the possibilities of employing the LysM domains for cell immobilization, for the display of peptides, proteins, or enzymes on (bacterial) surfaces as well as their utility in the development of novel vaccines have been scrutinized. To serve these purposes, the chimeric proteins containing one or more of the LysM sequences have been produced and isolated from various prokaryotic and eukaryotic expression hosts. This review gives a succinct overview of the characteristics of the LysM domain and of current developments in its application potential. Springer Berlin Heidelberg 2014-03-21 2014 /pmc/articles/PMC4004799/ /pubmed/24652063 http://dx.doi.org/10.1007/s00253-014-5633-7 Text en © The Author(s) 2014 https://creativecommons.org/licenses/by/4.0/ Open Access This article is distributed under the terms of the Creative Commons Attribution License which permits any use, distribution, and reproduction in any medium, provided the original author(s) and the source are credited.
spellingShingle Mini-Review
Visweswaran, Ganesh Ram R.
Leenhouts, Kees
van Roosmalen, Maarten
Kok, Jan
Buist, Girbe
Exploiting the peptidoglycan-binding motif, LysM, for medical and industrial applications
title Exploiting the peptidoglycan-binding motif, LysM, for medical and industrial applications
title_full Exploiting the peptidoglycan-binding motif, LysM, for medical and industrial applications
title_fullStr Exploiting the peptidoglycan-binding motif, LysM, for medical and industrial applications
title_full_unstemmed Exploiting the peptidoglycan-binding motif, LysM, for medical and industrial applications
title_short Exploiting the peptidoglycan-binding motif, LysM, for medical and industrial applications
title_sort exploiting the peptidoglycan-binding motif, lysm, for medical and industrial applications
topic Mini-Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4004799/
https://www.ncbi.nlm.nih.gov/pubmed/24652063
http://dx.doi.org/10.1007/s00253-014-5633-7
work_keys_str_mv AT visweswaranganeshramr exploitingthepeptidoglycanbindingmotiflysmformedicalandindustrialapplications
AT leenhoutskees exploitingthepeptidoglycanbindingmotiflysmformedicalandindustrialapplications
AT vanroosmalenmaarten exploitingthepeptidoglycanbindingmotiflysmformedicalandindustrialapplications
AT kokjan exploitingthepeptidoglycanbindingmotiflysmformedicalandindustrialapplications
AT buistgirbe exploitingthepeptidoglycanbindingmotiflysmformedicalandindustrialapplications